- Global Pharma News & Resources

Centers for Medicare & Medicaid Services open NCD review process for Epi proColon

Epigenomics AG / Key word(s): Miscellaneous
Centers for Medicare & Medicaid Services open NCD review process for Epi proColon

28-Feb-2020 / 23:02 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of inside information pursuant to Article 17 MAR

Centers for Medicare & Medicaid Services open NCD review process for Epi proColon

Berlin, 28.02.2020- Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that the Centers for Medicare & Medicaid Services (CMS) have opened the National Coverage Determination (NCD) review of Epi proColon, Epigenomics' blood test for colorectal cancer screening. This means that according to the statutes, a decision on CMS's reimbursement of Epi proColon must be made within a maximum period of nine months. A positive CMS reimbursement decision would represent a major breakthrough for the company in the commercialization of Epi proColon in the U.S. market.

Epigenomics AG, Geneststra├če 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, e-mail:

Investor Relations
IR.on AG, Frederic Hilke, Fabian Kirchmann, Tel +49 221 9140 970, e-mail:


Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

28-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Epigenomics AG
Geneststra├če 5
10829 Berlin
Phone: +49 30 24345-0
Fax: +49 30 24345-555
ISIN: DE000A11QW50
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 986827

End of Announcement DGAP News Service

Editor Details

Last Updated: 28-Feb-2020